Literature DB >> 7541256

Differential response of human basophils and mast cells to recombinant chemokines.

W Füreder1, H Agis, H Semper, F Keil, U Maier, M R Müller, K Czerwenka, H Höfler, K Lechner, P Valent.   

Abstract

Chemokines are proinflammatory peptides regulating the functions of various hematopoietic cells. We have analyzed the effects of seven recombinant human (rh) chemokines (MCAF, RANTES, MIP-1 alpha, MIP-1 beta, IL-8, GRO, and IP-10) on the growth and function of human basophils and mast cells. We found that MCAF, but not RANTES, MIP-1 alpha, MIP-1 beta, IL-8, GRO, or IP-10, causes direct and dose-dependent histamine release from basophils (MCAF, 5 micrograms/ml: 26.9 +/- 3.4%; other chemokines: < 5% of total histamine). An increased (2.1 to 3.5-fold) response to MCAF was obtained when basophils were preincubated with rh interleukin-3 (100 units/ml). Moreover, IL-3-primed basophils became responsive to physiologic concentrations (< 1 microgram/ml) of MCAF, IL-8, and RANTES. None of the chemokines tested was able to induce histamine secretion in mast cells obtained from lung (n = 2), skin (n = 1), uterus (n = 3), or tonsils (n = 3), even when cells had been preincubated with the mast cell agonist SCF. The chemokines also failed to modulate the expression of activation antigens (CD11b/C3biR, CD25/IL-2R beta, CD63, IL-3R alpha, CD117/c-kit) on the mast cell line HMC-1 or the basophil cell line KU-812 and were unable to induce differentiation of basophils or mast cells in culture. Together, our results show that basophils respond to rhIL-8, rhMCAF, and rhRANTES and that, unlike human basophils, human mast cells are unresponsive to recombinant chemokines.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7541256     DOI: 10.1007/bf01784044

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  45 in total

1.  Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes.

Authors:  P Valent; L K Ashman; W Hinterberger; F Eckersberger; O Majdic; K Lechner; P Bettelheim
Journal:  Blood       Date:  1989-05-15       Impact factor: 22.113

Review 2.  Chemokines and serpentines: the molecular biology of chemokine receptors.

Authors:  D J Kelvin; D F Michiel; J A Johnston; A R Lloyd; H Sprenger; J J Oppenheim; J M Wang
Journal:  J Leukoc Biol       Date:  1993-12       Impact factor: 4.962

Review 3.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils.

Authors:  M Baggiolini; A Walz; S L Kunkel
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

4.  Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression.

Authors:  H E Broxmeyer; B Sherry; S Cooper; L Lu; R Maze; M P Beckmann; A Cerami; P Ralph
Journal:  J Immunol       Date:  1993-04-15       Impact factor: 5.422

5.  Expression of multiple chemokine genes by a human mast cell leukemia.

Authors:  R S Selvan; J H Butterfield; M S Krangel
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

6.  The surface membrane antigen phenotype of human blood basophils.

Authors:  W Füreder; H Agis; W R Sperr; K Lechner; P Valent
Journal:  Allergy       Date:  1994-12       Impact factor: 13.146

7.  Macrophage inflammatory protein-1 alpha and monocyte chemoattractant peptide-1 elicit immediate and late cutaneous reactions and activate murine mast cells in vivo.

Authors:  R Alam; D Kumar; D Anderson-Walters; P A Forsythe
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

8.  Monocyte chemotactic and activating factor is a potent histamine-releasing factor for basophils.

Authors:  R Alam; M A Lett-Brown; P A Forsythe; D J Anderson-Walters; C Kenamore; C Kormos; J A Grant
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

9.  A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors.

Authors:  K Kishi
Journal:  Leuk Res       Date:  1985       Impact factor: 3.156

10.  Human lung mast cells: purification and characterization.

Authors:  E S Schulman; D W MacGlashan; S P Peters; R P Schleimer; H H Newball; L M Lichtenstein
Journal:  J Immunol       Date:  1982-12       Impact factor: 5.422

View more
  5 in total

1.  Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions.

Authors:  Dai Miyazaki; Takao Nakamura; Masako Toda; Kam-Wa Cheung-Chau; Ricardo M Richardson; Santa Jeremy Ono
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

2.  Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia.

Authors:  Jie Chao; Paula Donham; Nico van Rooijen; John G Wood; Norberto C Gonzalez
Journal:  Am J Respir Cell Mol Biol       Date:  2010-09-02       Impact factor: 6.914

Review 3.  Alveolar macrophages initiate the systemic microvascular inflammatory response to alveolar hypoxia.

Authors:  Jie Chao; John G Wood; Norberto C Gonzalez
Journal:  Respir Physiol Neurobiol       Date:  2011-03-21       Impact factor: 1.931

4.  Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E.

Authors:  Faisal M Khan; Aito Ueno-Yamanouchi; Bazir Serushago; Tom Bowen; Andrew W Lyon; Cathy Lu; Jan Storek
Journal:  Allergy Asthma Clin Immunol       Date:  2012-01-20       Impact factor: 3.406

5.  Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers.

Authors:  Jordi Roca-Ferrer; Laura Pujols; Maria Pérez-González; Isam Alobid; Borja Callejas; Sònia Vicens-Artés; Mireya Fuentes; Antonio Valero; César Picado; Dennis Castor; DucTung Nguyen; Joaquim Mullol
Journal:  Allergy Asthma Clin Immunol       Date:  2018-12-18       Impact factor: 3.406

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.